Milvexian

Milvexian is a factor XIa inhibitor which acts as an anticoagulant. It is taken by mouth. As of late 2021, it was under study for the prevention of blood clots in patients undergoing surgery.[2]

Milvexian
Clinical data
Other namesBMS-986177, JNJ-70033093
Routes of
administration
By mouth
ATC code
  • None
Legal status
Legal status
  • Investigational
Pharmacokinetic data
Elimination half-life11.4–18.1 h[1]
Identifiers
IUPAC name
  • (9R,13S)-13-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-6-oxo-1(6H)-pyrimidinyl}-3-(difluoromethyl)-9-methyl-3,4,7,15-tetraazatricyclo[12.3.1.02,6]octadeca-1(18),2(6),4,14,16-pentaen-8-one
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC28H23Cl2F2N9O2
Molar mass626.45 g·mol−1
3D model (JSmol)
SMILES
  • C[C@@H]1CCC[C@H](n2cnc(-c3cc(Cl)ccc3-n3cc(Cl)nn3)cc2=O)c2cc(ccn2)-c2c(cnn2C(F)F)NC1=O
InChI
  • InChI=1S/C28H23Cl2F2N9O2/c1-15-3-2-4-23(20-9-16(7-8-33-20)26-21(36-27(15)43)12-35-41(26)28(31)32)39-14-34-19(11-25(39)42)18-10-17(29)5-6-22(18)40-13-24(30)37-38-40/h5-15,23,28H,2-4H2,1H3,(H,36,43)/t15-,23+/m1/s1
  • Key:FSWFYCYPTDLKON-CMJOXMDJSA-N

References

  1. Perera V, Wang Z, Luettgen J, Li D, DeSouza M, Cerra M, Seiffert D (September 2021). "First-in-human study of milvexian, an oral, direct, small molecule factor XIa inhibitor". Clinical and Translational Science. doi:10.1111/cts.13148. PMID 34558200. S2CID 237617815.
  2. Weitz JI, Strony J, Ageno W, Gailani D, Hylek EM, Lassen MR, et al. (November 2021). "Milvexian for the Prevention of Venous Thromboembolism". The New England Journal of Medicine. doi:10.1056/NEJMoa2113194. PMID 34780683. S2CID 244132392.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.